Coya Therapeutics, Inc. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
Coya Therapeutics, Inc. (COYA) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of -$3.64 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-08-11
- Coya Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2026-03-31 was $3.90M.
- Coya Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-03-31 was -$2.81M, a 183.54% decline year-over-year.
- Coya Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-03-31 was $3.36M, a 67.63% decline year-over-year.
- Coya Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-03-31 was $10.39M.
- Coya Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2025 was $8.48M, a 48.49% increase from fiscal 2024.
- Coya Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was $5.71M, a 78.60% decline from fiscal 2023.
- Coya Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was $26.69M, a 1575.10% increase from fiscal 2022.
- Coya Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was $1.59M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$3.64M 10-Q · filed 2026-08-11 | |||
| 2026-03-31 | $3.90M 10-Q · filed 2026-05-12 | |||
| 2025-12-31 | $8.48M 10-K · filed 2026-03-16 | |||
| 2025-09-30 | -$10.21M 10-Q · filed 2025-11-12 | |||
| 2025-06-30 | -$8.58M 10-Q · filed 2026-08-11 | |||
| 2025-03-31 | -$2.81M 10-Q · filed 2026-05-12 | |||
| 2024-12-31 | $5.71M 10-K · filed 2026-03-16 | |||
| 2024-09-30 | -$1.57M 10-Q · filed 2025-11-12 | |||
| 2024-06-30 | $3.95M 10-Q · filed 2025-08-12 | |||
| 2024-03-31 | $3.36M 10-Q · filed 2025-05-13 | |||
| 2023-12-31 | $26.69M 10-K · filed 2025-03-18 | |||
| 2023-09-30 | $4.95M 10-Q · filed 2024-11-06 | |||
| 2023-06-30 | $7.17M 10-Q · filed 2024-08-12 | |||
| 2023-03-31 | $10.39M 10-Q · filed 2024-05-09 | |||
| 2022-12-31 | $1.59M 10-K · filed 2024-03-19 | |||
| 2022-09-30 | $4.31M 10-Q · filed 2023-11-08 | |||
| 2022-06-30 | $6.05M 10-Q · filed 2023-08-08 | |||
| 2022-03-31 | -$2.05M 10-Q · filed 2023-05-10 | |||
| 2021-12-31 | -$4.38M 10-K · filed 2023-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |